Flag of the European Union EU Clinical Trials Register Help

Clinical trials for triple negative breast cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    228 result(s) found for: triple negative breast cancer. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-004194-16 Sponsor Protocol Number: IRFMN-BRC-6591 Start Date*: 2015-01-19
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: A multicenter, single-arm, phase II study to evaluate the activity of pre-operative zoledronate in triple negative breast cancer patients, according to p53 level
    Medical condition: Newly diagnosed, untreated, operable triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001463-75 Sponsor Protocol Number: ICO-2019-04 Start Date*: 2020-02-03
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST
    Full Title: Pilot Feasibility Study: Inflammation and presence of M2 macrophages explorations with[18F]-DPA-714 PET/CT in Triple Negative breast cancers
    Medical condition: Patients with Triple Negative Breast Cancer prior to surgical treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000698-57 Sponsor Protocol Number: MDV3100-11 Start Date*: 2013-09-01
    Sponsor Name:Medivation, Inc.
    Full Title: A Phase 2, Single-Arm, Open-Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple-Negative Breast Cancer
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) IT (Completed) IE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-002377-21 Sponsor Protocol Number: M14-011 Start Date*: 2014-11-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant...
    Medical condition: Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) HU (Completed) GB (GB - no longer in EU/EEA) ES (Completed) IT (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-000677-23 Sponsor Protocol Number: CLCL161A2201 Start Date*: 2012-10-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II, multi-center, open-label, neoadjuvant, randomized study of weekly paclitaxel with or without LCL161 in patients with triple negative breast cancer
    Medical condition: Triple negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) IE (Completed) IT (Completed) BE (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006262-28 Sponsor Protocol Number: IEO S438/508 Start Date*: 2009-06-03
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Allogeneic Haematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Refractory “Triple Negative”...
    Medical condition: Patients with Refractory “Triple Negative” Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022065-10 Sponsor Protocol Number: SABO-2010-01 Start Date*: 2011-08-02
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: Effect of angiogenesis inhibiting therapy in patients progressing on endocrine treatment and patients with triple negative breast cancer - a translational phase II study within the Swedish Associa...
    Medical condition: Patients with breast cancer who are oestrogen receptor positive but HER2 negative and progressing on endocrine therapy. Patients with locally advanced or recurrent triple negative breast cancer (TN...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005200-19 Sponsor Protocol Number: I-CONIC Start Date*: 2022-05-09
    Sponsor Name:Västra Götalandsregionen/Onkologiska kliniken
    Full Title: Use of Imatinib to convert triple negative breast cancer into ER-positive breast cancer - "I-CONIC"
    Medical condition: Early Triple Negative Breast Cancer planned for surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001226-25 Sponsor Protocol Number: HD-TNBC-TRIAL Start Date*: 2015-04-20
    Sponsor Name:ISTITUTI OSPITALIERI DI CREMONA
    Full Title: A phase II randomized, open-label neo-adjuvant study of standard chemotherapy regimen compared to high dose chemotherapy regimen with autologous stem cell transplantation in patients with triple ne...
    Medical condition: Triple Negative Breast Cancer patients with breast tumor >2,5 cm
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014279-37 Sponsor Protocol Number: ML22780 Start Date*: 2009-12-07
    Sponsor Name:Roche Products Limited
    Full Title: Open-Label study of bevacizumab (Avastin®) and taxane monotherapy for the first-line treatment of patients with advanced triple-negative breast cancer
    Medical condition: Advanced triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004220-34 Sponsor Protocol Number: TNPET01 Start Date*: 2012-01-19
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas' NHS Foundation Trust
    Full Title: A randomised phase II trial of [18F]fluorothymidine and the standard tracer [18F]Fluorodeoxyglucose in the assessment of systemic therapy response in triple negative breast cancer and their utility...
    Medical condition: Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000062-24 Sponsor Protocol Number: D0810C00021 Start Date*: 2008-10-27
    Sponsor Name:AstraZeneca AB
    Full Title: Ensayo fase I/II, abierto, multicéntrico, de AZD2281 oral en combinación con Cisplatino, para valorar la seguridad y tolerabilidad en pacientes con tumores sólidos avanzados, y para valorar la efic...
    Medical condition: Tumores sólidos avanzados, cáncer de mama triple negativo Advanced Solid Tumours, Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004358-32 Sponsor Protocol Number: IJB–TNBC–1–RHEA Start Date*: 2015-05-07
    Sponsor Name:Institut Jules Bordet
    Full Title: Biomarker Research Study for PF-03084014 in cHEmoresistant triple negative breast cAncer - “RHEA” study
    Medical condition: patients with chemoresistant, triple-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002080-25 Sponsor Protocol Number: NBG-19-01 Start Date*: 2019-06-26
    Sponsor Name:Skåne University Hospital
    Full Title: A TRANSLATIONAL RANDOMIZED PHASE III STUDY EXPLORING THE EFFECT OF THE ADDITION OF CAPECITABINE TO CARBOPLATINUM BASED CHEMOTHERAPY IN EARLY “TRIPLE NEGATIVE” BREAST CANCER.
    Medical condition: Early triple negative breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022077-33 Sponsor Protocol Number: CaPaBe Start Date*: 2011-01-20
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: Phase II, open label, study of primary chemotherapy with Bevacizumab in association with carboplatin, paclitaxel in early and locally advanced triple negative (ER, PgR and HER2 negative) breast ca...
    Medical condition: Patient with early and locally advanced triple negative (ER, PgR and HER2 negative) breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020835-38 Sponsor Protocol Number: IEOS550310 Start Date*: 2011-09-30
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: “A phase II study of cisplatin plus cyclophospamide for patients with previously treated, advanced, triple receptor negative breast cancer”
    Medical condition: Advanced, triple receptor negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000469-35 Sponsor Protocol Number: GO29227 Start Date*: 2014-08-12
    Sponsor Name:Genentech, Inc.
    Full Title: A RANDOMIZED, PHASE II, MULTICENTER, PLACEBO-CONTROLLED STUDY OF IPATASERTIB (GDC-0068), AN INHIBITOR OF AKT, IN COMBINATION WITH PACLITAXEL AS FRONT-LINE TREATMENT FOR PATIENTS WITH METASTATIC TRI...
    Medical condition: Inoperable locally advanced or metastatic triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10027475 Metastatic breast cancer LLT
    17.0 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) BE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-002221-23 Sponsor Protocol Number: CT 4002 Start Date*: 2006-12-28
    Sponsor Name:MediGene AG
    Full Title: An open-label, randomized, controlled Phase-II trial evaluating the efficacy and safety of EndoTAG-1 in triple receptor negative breast cancer patients
    Medical condition: Patients with triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) DE (Completed) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005213-39 Sponsor Protocol Number: CJP4.2 Start Date*: 2013-04-10
    Sponsor Name:CENTRE JEAN PERRIN
    Full Title: Phase II pilot study assessing efficacy of a Cisplatine – Métronomic Cyclophosphamide treatment in Patients with Stade IV Triple Negative breast Cancer Secondary Resistant to Anthracyclines and T...
    Medical condition: Triple negative metastatic breast cancer resistant secondary to anthracyclines and taxanes
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020101-32 Sponsor Protocol Number: OAM4861g Start Date*: 2010-10-21
    Sponsor Name:GENENTECH, Inc.
    Full Title: A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF METMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB IN PATIENTS WITH METASTATIC, ...
    Medical condition: Metastatic, triple-negative breast cancer Cáncer de mama metastásico triple negativo
    Disease: Version SOC Term Classification Code Term Level
    12.1 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) FR (Completed) BE (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 04 04:26:09 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA